Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803, ETBX-071, and M-CENK with Radiation in High-Risk Prostate Cancer
NCT06765954Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2025
- Primary completion
- Jan 2031
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
01
Overview
Phase 2, open-label, single-arm trial of nogapendekin alfa inbakicept, adenovirus PSA vaccine and M-CENK in prostate cancer (PCa), sponsored by ImmunityBio, Inc. Primary endpoints: Complete Pathologic Response at 6 weeks and PSA30 response at 39 weeks. Planned start Dec 2025; status: withdrawn.
02
Drugs
nogapendekin alfa inbakiceptadenovirus PSA vaccineM-CENK
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06765954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765954.